An interview with Ranbaxy CEO and MD Arun Sawhney on the changes in the past four years and how the company plans to address the US concerns.
SFIO official refuses to reveal the nature of additional charges found during investigation.
Sharad Pawar says final draft will go to Cabinet before Tuesday.
Company refuses to comment, says 'matters internal to organisation'
Another cap for imported insulin; domestic manufacturers cry foul.
FinMin had objected and wanted existing cost-plus method retained.
CCI to examine competition part of deals, RBI prudential aspects.
Work to begin after that on corrective measures to meet US regulator's requirements.
Note proposes more checks, transparent data bank in land sale or lease.
The prime minister's scientific advisory council had advocated introduction of GM crops in India, but under strict regulatory mechanism.
USFDA has extended the timeline for granting tentative approval to generic drug applications filed under Para IV of its rules by 10 months.
To buy 200,000 tonnes by December but long-term deal prospects stuck on quality concerns; govt to consult labs
Sun Pharma could have to withdraw cancer drug as J&J re-enters after temporary eclipse
Now, the companies need to get National Pharmaceutical Pricing Authority's nod for changing medicine composition. If they flout norms, government will take penal action.
Food Min says decision on Rangarajan panel's report in a time bound manner.
While many experts said the suggestion would go a long way in bringing down the annual food subsidy expenditure, they doubt the feasibility of the idea.
GoM had proposed a new pricing mechanism, but judges had said at an earlier hearing the current formula should stay.
Ranbaxy was scheduled to launch its drug on September 21, the day Diovan's patent expired.
The move is significant, as this may prompt investigating agencies to take a look at the fresh accounting statements to be filed by the company to RoC, before taking a final call.
It was in 2005, India changed its patent law and started granting patents in medicines.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances